Inhaled nitric oxide in therapy of pediatric and neonatal acute respiratory distress syndrome: the good, the bad and the ugly
While iNO can improve oxygenation, its routine use is not recommended due to uncertain long-term benefits. Future, rigorous trials must identify predictive biomarkers and patient subgroups most likely to benefit, paving the way for personalized iNO therapy in neonatal and pediatric critical care.
Authors
- Jun Wang (ORCID: https://orcid.org/0000-0001-7564-2364)
- Wenwen Tang (ORCID: https://orcid.org/0000-0001-9234-4385)
- Xiaoyan Gao (ORCID: https://orcid.org/0000-0003-1172-4648)
- George H. Lorimer (ORCID: https://orcid.org/0000-0003-2805-8792)
- Hasan Bayram (ORCID: https://orcid.org/0000-0002-5236-766X)
- Liang Chen (ORCID: https://orcid.org/0000-0003-1553-2846)
- Qiang He (ORCID: https://orcid.org/0000-0001-5901-5627)
- Bingbing Li (ORCID: https://orcid.org/0000-0002-9224-2685)
- Shuang Liu (ORCID: https://orcid.org/0009-0001-4284-7897)
Institutions
- Autism Research Institute (US)
- Koç University (TR)
- University of Maryland, College Park (US)
- Hubei University of Technology (CN)
Publication Details
- Journal
- Expert Review of Respiratory Medicine
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1080/17476348.2025.2583353
- Primary Topic
- Respiratory Support and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00